Search
for
Sort by
Research 31–60 of 1000+
- GRHL3 binding and enhancers rearrange as epidermal keratinocytes transition between functional states
- Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice
- Novel inhibitors of 5α-reductase
- N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase
- Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review
- Sulfatase inhibitors: a patent review
- FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
- Synthesis and in Vitro Evaluation of 4-Substituted N-(1,1-Dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides as 5.alpha.-Reductase Inhibitors and Antiandrogens
- Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors
- 12 Treatment of hirsutism with 5α-reductase inhibitors
- 5α- Reductase Inhibitors in Prostate Cancer: An Overview
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- New 5?-reductase inhibitors: In vitro and in vivo effects
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
- Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink
- 5α-Reductase Inhibitors, Chemical and Clinical Models
- 5α-Reductase inhibitors in androgenetic alopecia
- Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- Incomplete Recovery of Erectile Function in Rat after Discontinuation of Dual 5‐Alpha Reductase Inhibitor Therapy
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry
- Natural Product-Inspired Bis(trifluoromethyl) Phenyl Hydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitors of Human Steroid 5α-Reductase Type-1: Synthesis, <i>In Vitro</i>, and <i>In Silico</i> Studies